Clinical trials: Non-Small Cell Lung
Brain Metastases
Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy
1. Patients with confirmed advanced NSCLC and any response to 3-6 cycles of chemotherapy, were randomized to receive PCI (30 Gy/10fr) or no PCI. 2.
- Trial name
- PCI (NCT00745797)
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Yi-Long Wu
Non-small Cell Lung Cancer
Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer
The goal of this trial is to design and test a telehealth nurse navigation intervention for patients with suspected locally advanced/metastatic NSCLC to improve timely molecularly-informed treatment recommendations through early…
- Trial name
- TESTING (NCT05790460)
- Testing
- Telehealth
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Non-Small-Cell Lung
Genetic Predictors of Benefit to Pembrolizumab
The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy.
- Trial name
- NCT02710396
- Testing
- Pembrolizumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Columbia University
Non Small Cell Lung Cancer, KRAS Gene Mutation
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
- Trial name
- NCT03704688
- Testing
- Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Both pemetrexed and cetuximab have single agent activity in NSCLC and non-overlapping toxicity profiles. While 2-drug combination therapy has proven superior to single agent therapy in the first-line setting of NSCLC, no such…
- Trial name
- NCT00216203
- Testing
- Pemetrexed, Cetuximab
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Nasser Hanna, M.D.
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with…
- Trial name
- NCT06069570
- Testing
- KB-GDT-01
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Kiromic BioPharma Inc.
Non-Small Cell Lung Cancer
Exemestane in Post-Menopausal Women With NSCLC
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab…
- Trial name
- NCT02666105
- Testing
- Exemestane
- Where
- 18 sites in United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal…
- Trial name
- NCT00547105
- Testing
- Erlotinib, SBRT
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer Metastatic
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or…
- Trial name
- NCT03656094
- Testing
- Pembrolizumab plus chemotherapy
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Samsung Medical Center
NSCLC
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
The aim of this study is to explore the Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.
- Trial name
- NCT01769066
- Testing
- Sequential Gefitinib With Pemetrexed/Platinum, Pemetrexed/Platinum
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Fudan University
Metastatic Non-Small Cell Lung Carcinoma
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
This is a single center, open-label, single arm study in patients with metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 after failure of platinum-based combination chemotherapy.
- Trial name
- NCT03134456
- Testing
- Pembrolizumab Injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Non Small Cell Lung Cancer (NSCLC)
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in…
- Trial name
- NCT01741155
- Testing
- SPI-1620, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Esophageal Cancer, Non-small Cell Lung Cancer
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during…
- Trial name
- NCT01065818
- Testing
- Fluoro-L-Thymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Non-small Cell Lung Cancer (NSCLC), Lung Metastasis
Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study
This research study is being conducted to assess the safety and feasibility of using a newly developed bronchoscopic light delivery method of photodynamic therapy to treat subjects with solid tumors in peripheral lung, who are…
- Trial name
- NCT04753918
- Testing
- Porfimer sodium, Ethiodized oil, Novel light delivery methods of photodynamic therapy
- Volunteers
- 3 people
- Sponsor
- Taoyuan General Hospital
Advanced Tumors, Melanoma
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a…
- Conditions
- Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease
- Trial name
- NCT04198818
- Testing
- HH2710
- Where
- 3 sites in United States, China
- Volunteers
- 37 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Lung Cancer
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06321510
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Non-Small-Cell Lung Carcinoma
A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.
- Trial name
- NCT00112060
- Testing
- PT-523 for Injection
- Where
- 13 sites in United States, Russia
- Sponsor
- Spectrum Pharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.